Welcome to our dedicated page for DOCGO SEC filings (Ticker: DCGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing DocGo’s multi-segment disclosures can feel like treating a patient without a chart. The company’s mobile health contracts, ambulance fleet costs, and virtual-care metrics often sit side-by-side in a single document. Whether you’re hunting for how a new city contract shows up in an 8-K or comparing Mobile Health margins across quarters, the details are deep. That’s why investors search for "DocGo SEC filings explained simply"—and why Stock Titan starts by translating the technical language.
Our AI reads every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR. Within seconds you’ll see
- AI-powered summaries that surface segment revenue, payer mix, and fleet expansion costs
- Real-time alerts on "DocGo Form 4 insider transactions real-time" for fast trade monitoring
- Expert notes that turn complex healthcare reimbursement tables into plain English
Investors routinely ask about "DocGo insider trading Form 4 transactions" and "DocGo proxy statement executive compensation" to gauge management’s incentives. Others want the "DocGo annual report 10-K simplified" or "DocGo 8-K material events explained" to understand how new municipal deployments could shift revenue. By "understanding DocGo SEC documents with AI," you’ll pinpoint which units drive growth, track "DocGo executive stock transactions Form 4," and monitor cash burn tied to ambulance acquisitions—information that can influence valuation well before the next earnings call.
DocGo Inc.'s Chief Executive Officer and director Lee Bienstock reported equity awards and related tax withholding transactions in the company’s common stock. On December 12, 2025, he received 1,113,495 restricted stock units (RSUs) under DocGo’s 2021 Stock Incentive Plan, which will vest in four equal annual installments on each of the first four anniversaries of December 12, 2025. Each RSU entitles him to receive one share of DocGo common stock upon vesting.
On December 15, 2025, 214,131 RSUs were withheld at a price of $0.91 per share to satisfy his tax liability from RSUs granted on December 12, 2023 and December 12, 2024. After these transactions, Bienstock beneficially owns 2,836,281 shares of DocGo common stock directly, including previously granted RSUs scheduled to vest on various dates between March 28, 2026 and December 12, 2028 under the plan.
DocGo Inc.'s CFO and Treasurer, Norman Rosenberg, reported equity compensation and related tax withholding transactions. On December 12, 2025, he received 429,405 restricted stock units (RSUs) under DocGo’s 2021 Stock Incentive Plan at a stated price of $0, bringing his beneficial ownership to 1,289,345 shares of common stock.
On December 15, 2025, 65,774 shares were withheld at $0.91 per share to cover his tax liability from earlier RSU grants, reducing his beneficial ownership to 1,223,571 shares. The new RSUs vest in four equal annual installments on each of the first four anniversaries of December 12, 2025, and additional previously granted RSUs are scheduled to vest between December 2026 and December 2028.
DocGo Inc.'s chief compliance officer, Stephen Sugrue, reported new equity awards and related tax withholding. On December 12, 2025, he received 321,055 restricted stock units (RSUs) under the 2021 Stock Incentive Plan, vesting in four equal annual installments starting on the first anniversary of that date. Each RSU represents the right to receive one share of common stock upon vesting.
On December 15, 2025, 35,968 RSUs were withheld at a price of $0.91 per share to satisfy his tax liability from earlier RSU grants. After these transactions, Sugrue beneficially owns 636,602 shares of DocGo common stock, including additional RSUs scheduled to vest between December 2026 and December 2028.
DocGo Inc. reported that director and officer Ely D. Tendler received 100,000 restricted stock units on December 12, 2025 under the company’s 2021 Stock Incentive Plan. These units vest in four equal annual installments on each of the first four anniversaries of that date, with each unit delivering one share of common stock when it vests.
On December 15, 2025, Tendler sold 16,850 shares of common stock at $0.91 to cover taxes due on vested units from earlier grants made in 2023 and 2024. After these transactions, he beneficially owned 258,795 DocGo shares and restricted stock units in total, including additional awards scheduled to vest in 2026 and 2027.
DocGo Inc. director Michael J. Burdiek received 150,000 shares of common stock in the form of restricted stock units (RSUs) on December 12, 2025. These RSUs were granted at a price of $0 under DocGo's 2021 Stock Incentive Plan and are scheduled to vest on December 12, 2026, subject to the plan's terms. Each RSU represents the right to receive one share of DocGo common stock upon vesting. Following this grant, Burdiek beneficially owns 791,560 shares of DocGo common stock directly.
DocGo Inc. director Etalvina Leite received an equity award in the form of restricted stock units. On December 12, 2025, Leite was granted 150,000 restricted stock units of DocGo common stock at a grant price of $0 under the company’s 2021 Stock Incentive Plan. These RSUs are scheduled to vest on December 12, 2026, and each unit will convert into one share of common stock upon vesting, subject to the plan’s terms. Following this award, Leite beneficially owns 201,411 shares of DocGo common stock, held directly.
DocGo Inc. director Ira Smedra reported a new equity award. On December 12, 2025, he received 150,000 restricted stock units ("RSUs") of DocGo common stock at a price of $0 per unit.
The RSUs were granted under DocGo’s 2021 Stock Incentive Plan and will vest on December 12, 2026, as long as the plan’s conditions are met. Each RSU represents the right to receive one share of DocGo common stock upon vesting. After this grant, Smedra beneficially owns 240,999 shares of DocGo common stock directly.
DocGo Inc. director James M. Travers reported a new equity award from the company. On December 12, 2025, he was granted 150,000 restricted stock units (RSUs) of DocGo common stock under the issuer’s 2021 Stock Incentive Plan at a price of $0 per unit.
Each RSU represents the right to receive one share of common stock upon vesting on December 12, 2026, subject to the plan’s terms. Following this grant, Travers beneficially owns 240,999 shares of DocGo stock directly and 391,028 shares indirectly through Travers Holdings LLC, over which he and Susan D. Travers share voting and dispositive power while each disclaiming beneficial ownership of those securities except to the extent of any pecuniary interest.
DocGo Inc. extended the expiration date of its existing share repurchase program from December 31, 2025 to June 30, 2026. The program continues to authorize the company to repurchase up to $26 million of its common stock.
DocGo may buy shares from time to time through open-market purchases, privately negotiated transactions, or arrangements such as Rule 10b5-1 trading plans and accelerated share repurchase programs, during trading windows when it is not in possession of material non-public information. Repurchases may be funded with existing cash and cash equivalents, future cash flow, or proceeds of borrowings or debt offerings, and the program can be modified, suspended, or discontinued at any time.
DocGo (DCGO) reported a sharp year-over-year contraction in Q3 2025. Revenue was $70.8M versus $138.7M a year ago, driven by a steep drop in Mobile Health Services to $20.7M from $90.7M, while Transportation Services delivered $50.1M vs $48.0M. The company posted a net loss attributable to stockholders of $27.8M compared with $5.5M income a year earlier, reflecting lower volume and non-cash charges.
Management recorded a $8.7M goodwill impairment tied to the Rapid Temps reporting unit and a $8.0M impairment of finite‑lived intangibles in Mobile Health Services. For the nine months, revenue was $247.3M vs $495.7M, with a $48.3M loss to stockholders. Cash from operations was $44.9M, supported by a large reduction in accounts receivable. The balance sheet showed cash and cash equivalents of $73.4M, total assets of $353.8M, and no outstanding line of credit at quarter‑end. Shares outstanding were 97,813,372 as of November 7, 2025.
FAQ
What is the current stock price of DOCGO (DCGO)?
What is the market cap of DOCGO (DCGO)?
